- Conditions
- Achondroplasia
- Interventions
- Navepegritide (TransCon CNP), Placebo for Navepegritide (TransCon CNP)
- Drug
- Lead sponsor
- Ascendis Pharma Growth Disorders A/S
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Saint Paul, Minnesota • Columbia, Missouri • Houston, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Achondroplasia
- Interventions
- TransCon CNP
- Drug
- Lead sponsor
- Ascendis Pharma Growth Disorders A/S
- Industry
- Eligibility
- 3 Years to 15 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2039
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • Wilmington, Delaware + 5 more